NCT00642954 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Participants received vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG000
- title
- Level 1: Vorinostat 300 mg + Lenalidomide 10 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG001
- title
- Level 2: Vorinostat 400 mg + Lenalidomide 10 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG002
- title
- Level 3: Vorinostat 400 mg + Lenalidomide 15 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG003
- title
- Level 4: Vorinostat 400 mg + Lenalidomide 20 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle. Treatment continued until progressive disease or unacceptable toxicity.
- id
- FG004
- title
- Level 5: Vorinostat 400 mg + Lenalidomide 25 mg
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 9
- type
- Progressive Disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 6
- type
- Adverse Event
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 17
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 16
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Participants received vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG000
- title
- Level 1: Vorinostat 300 mg + Lenalidomide 10 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG001
- title
- Level 2: Vorinostat 400 mg + Lenalidomide 10 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG002
- title
- Level 3: Vorinostat 400 mg + Lenalidomide 15 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles.
- id
- FG003
- title
- Level 4: Vorinostat 400 mg + Lenalidomide 20 mg
- description
- Participants received vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle. Treatment continued until progressive disease or unacceptable toxicity.
- id
- FG004
- title
- Level 5: Vorinostat 400 mg + Lenalidomide 25 mg
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 9
- type
- Progressive Disease
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 6
- type
- Adverse Event
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 17
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 1
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 16
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle